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essary and sufficient set of signals that need to be delivered 
at the injury or defect site and should thus form the basis to 
define release criteria for reproducibly effective engineered 
bone graft substitutes.  Copyright © 2012 S. Karger AG, Basel
 Introduction
 Unlike other tissues, bones possess the capacity for re-
generation, remodeling and repair in response to injury 
in adults and in children alike  [1, 2] . The most common 
cause of bone regeneration is fracture healing, which oc-
curs through intramembranous and/or endochondral 
ossification. The majority of bone injuries and fractures 
can heal without formation of scar tissue within a certain 
timeframe. The healing process restores the bone with its 
original physicochemical properties leading to newly 
formed tissue indistinguishable from the adjacent healthy 
bone. However, in some cases, bone regeneration is com-
promised. Generally, the risk is reported to be around 
5–10%, reaching up to 40% in patients with typical risk 
factors like smoking or diabetes  [3–5] . Several biome-
chanical and biological factors are associated with the de-
velopment of a delayed union or non-union. This occurs 
when the required bone regeneration exceeds the natural 
potential for self-healing, as in large bone defects occur-
ring after trauma, infection, tumor resection  [6] or skel-
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 Abstract
 Despite the compelling clinical needs in enhancing bone re-
generation and the potential offered by the field of tissue 
engineering, the adoption of cell-based bone graft substi-
tutes in clinical practice is limited to date. In fact, no study 
has yet convincingly demonstrated reproducible clinical 
performance of tissue-engineered implants and at least 
equivalent cost-effectiveness compared to the current treat-
ment standards. Here, we propose and discuss how tissue 
engineering strategies could be evolved towards more effi-
cient solutions, depicting three different experimental para-
digms: (i) bioreactor-based production; (ii) intraoperative 
manufacturing, and (iii) developmental engineering. The de-
scribed approaches reflect the need to streamline graft 
manufacturing processes while maintaining the potency of 
osteoprogenitors and recapitulating the sequence of bio-
logical steps occurring during bone development, including 
vascularization. The need to combine the assessment of ef-
ficacy of the different strategies with the understanding of 
their mechanisms of action in the target regenerative pro-
cesses is highlighted. This will be crucial to identify the nec-
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etal abnormalities, or when the regenerative process is 
compromised due to various reasons, e.g. avascular ne-
crosis, osteoporosis and other local or systemic patholo-
gies. In all these cases, the supply of additional bone 
grafts is required for repair.
 The current clinical gold standard to treat bone de-
fects, e.g. in orthopedic and trauma surgery, consists in 
the transplantation of autologous bone grafts used as os-
teogenic substitutes. Typical examples of autologous bone 
grafts are structural grafts like the corticocancellous iliac 
crest or vascularized fibular grafts, and non-structural 
cancellous bone grafts that can be harvested either lo-
cally (e.g. in spinal or hip replacement surgery) or from 
the iliac crest. Unfortunately, all these techniques are as-
sociated with the limited availability of autologous mate-
rial  [7, 8] and considerable morbidity at the donor site, 
such as additional blood loss, which might reach signifi-
cance in patients with co-morbidities, chronic pain, iliac 
wing fractures or infections  [9–13] . Allo- or xenografts 
are available, but despite the development of screening 
methods for contamination and a production procedure 
following good manufacturing practices, concerns about 
pathogen transmission and immunogenicity of such 
grafts still remain  [14] . Synthetic and natural polymeric 
scaffolds can potentially avoid such risks but they lack 
most of the actual osteoinductive or osteogenic proper-
ties of autologous bone chips  [15] . Another approach is 
the use of recombinant growth and differentiation fac-
tors, e.g. recombinant human bone morphogenetic pro-
tein-2 (BMP-2), which are able to induce osteogenesis by 
resident progenitor cells, but which have been associated 
with aberrant bone formation  [16] , neurotoxicity  [17] , 
cancer development  [18] , high costs and a short half-life, 
rendering fine-tuning of the local application difficult 
 [19, 20] .
 Tissue engineering has emerged as an attractive alter-
native, possibly improving the results of current tech-
niques. Engineering of bone graft substitutes is typically 
based on bone marrow-derived autologous osteoprogen-
itors (mesenchymal stromal cells, MSC) expanded in 
plastic dishes and combined with osteoconductive scaf-
folds in order to generate living grafts, possibly analogues 
of autologous bone. Despite validation of this approach in 
several small- and large-size animal models, as well as in 
a few clinical cases  [21] , its routine clinical implementa-
tion is challenging, and very few studies were able to dem-
onstrate its efficacy in bone matrix production, either be-
cause it did not occur or because no biopsy to document 
it could be analyzed  [22–25] . The lack of demonstrated 
reproducibility and cost-effectiveness is reflected in the 
limited number of clinical cases of bone defects treated 
using cell-based grafts  [26] .
 The next sections of this paper describe and discuss 
three alternative approaches currently pursued by the au-
thors to evolve classical tissue engineering paradigms to-
wards possibly more effective products: (i) bioreactor-
based manufacture, aimed at the development of au-
tomated and controlled bone graft production; (ii) 
intraoperative graft manufacture, which does not require 
a graft production phase, since the graft is assembled 
during the surgical procedure, and (iii) developmental 
engineering, which relies on the biological rationale of 
recapitulating normal bone regeneration ( fig. 1 ). 
 Bioreactor-Based Production
 The issues of manufacturing, reproducibility, quality 
and costs have been addressed in other biotechnology 
sectors by the introduction of automated and controlled 
production environments, typically referred to as ‘biore-
actors’. Bioreactors have been proposed as a possible tool 
to develop cell-based therapeutic approaches towards a 
broader clinical adoption  [27] . The possibility of con-
trolled culture conditions would improve the regulation 
of the bioprocess and minimize graft product variability. 
Monitoring systems would be instrumental to implement 
traceability and safety compliance, whereas process auto-
mation would target standardization, scaling-up and 
possibly cost-effectiveness. The latter represents the crit-
ical and ultimate target among the various criteria for 
reimbursement policies by healthcare systems. 
 The industrialization within bioreactors of a previous-
ly established and validated manufacturing process, 
however, is expected to require a revalidation of the re-
sulting products, including new preclinical and clinical 
tests, and likely resulting in robotic systems which mere-
ly replicate the sometimes ineffective manual procedures. 
The challenge is thus to adopt effective automation with-
in bioreactors early in the development of a clinical pro-
gram. This strategy requires a higher investment upfront 
but also a streamlined pathway to the clinical use and 
possibly the introduction of more effective manufactur-
ing processes  [28] .
 As an example of the considerations above in the spe-
cific context of bone tissue engineering, we have demon-
strated that the use of perfusion-based bioreactor systems 
for the seeding and culture of MSC within porous 3D 
scaffolds allows to entirely bypass the phase of cell expan-
sion in monolayers, typically associated with a progres-
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sive loss of osteogenic differentiation capacity  [29] . The 
possibility to avoid MSC expansion in monolayers on stiff 
plastic not only streamlined the manufacturing process 
but also supported a superior maintenance of progenitor 
properties in MSC expanded under 3D perfusion culture 
 [30] . In particular, probably due to the interaction with 
an environment better resembling the native stromal tis-
sue, 3D-expanded MSC retained a higher clonogenicity 
(i.e. the capacity to form clonal strains under low-density 
plating conditions) compared to the state-of-the-art con-
trol established using cells from the same donors  [30] . 
Moreover, grafts generated under 3D perfusion and im-
planted ectopically in nude mice generated higher and 
more spatially uniform amounts of bone tissue, with su-
perior reproducibility across different donors. 
 Cells from the stromal vascular fraction (SVF) of adi-
pose tissue were also tested in the perfusion bioreactor 
system for the possibility of a streamlined manufacturing 
of osteogenic grafts. One advantage in using SVF as op-
posed to bone marrow cells lies in the superior amount of 
mesenchymal progenitors which can be available under 
minimally invasive conditions (1 ml of a lipoaspirate con-
tains about 100-fold higher numbers of clonogenic mes-
enchymal progenitors than 1 ml of bone marrow). The 
large availability of cells allowed the generation of osteo-
genic grafts under perfusion culture in 5 days as opposed 
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 Fig. 1. Schematic drawing depicting the canonical tissue engineering approach ( a ); the streamlined bioreactor-
based approach ( b ); the intraoperative approach ( c ) and the developmental engineering approach ( d ). 
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to the typical 3 weeks necessary for bone marrow-derived 
MSC  [31] . One additional important advantage of SVF 
cells consists in the presence (among the heterogeneous 
mix of phenotypes) of endothelial lineage cells. These 
cells, which are typically lost in monolayer cultures but 
are preserved during 3D perfusion cultivation, were 
shown to contribute to the formation of blood vessels rap-
idly anastomosing with those from the recipient site  [31] . 
The resulting process of inosculation supported an en-
hanced engraftment of large grafts (1 cm in diameter/
1-cm-thick cylinders) and a deeper formation of bone os-
sicles compared to conditions excluding endothelial cells 
 [32] . 
 The results presented above urge for the development 
of bioreactor systems compatible with good manufactur-
ing practices, possibly relying on the principle of 3D per-
fusion culture and allowing for clinical tests of the inno-
vative strategies and streamlined manufacturing pro-
cesses. The task is not trivial, as it requires the critical 
consideration of scientific, technical, regulatory and 
commercial challenges  [28, 33] . Among these are (i) the 
identification and validation of online quality control 
tests which may be predictive of functional performance, 
(ii) the qualification of in-process monitoring and control 
systems, (iii) the compliance to yet ambiguous safety and 
regulatory guidelines, (iv) the development of friendly in-
terfaces between the complex manufacturing system and 
the clinicians, and (v) the need of large upfront invest-
ments combined with the uncertainties of the markets, 
reimbursement policies and overall clinical adoption. 
 Intraoperative Manufacturing
 The intraoperative approach derives from the concept 
of cell and tissue transplantation. It exploits the fact that 
the engineering of an autologous bone graft can become 
more practical and less costly if the manufacturing pro-
cess, including isolation of autologous cells, generation of 
the graft and its implantation in the bone defect, can be 
combined with the procedure intended to surgically treat 
the bone defect itself. It allows eliminating the resource- 
and time-consuming in vitro expansion phase; instead, 
the patient’s body is used an in vivo bioreactor system to 
support the expansion and the differentiation of cells 
freshly harvested and directly transplanted into the bone 
defect.
 The critical point in this scenario is the challenging 
task of identifying a suitable autologous cell source. These 
cells have to possess an intrinsic osteogenic capacity in 
vivo without prior culture or osteoinduction and need to 
be available in sufficient quantities directly upon isola-
tion. The use of freshly isolated bone marrow-derived 
MSC, which were possibly harvested using a reamer-irri-
gator-aspirator  [34, 35] , concentrated by immunoselec-
tion  [36] or modified genetically  [24] , was proposed in 
such bone repair approaches. Despite the data collected 
so far in animal models about bone formation by im-
planted cells, a major limitation remains: clonogenic 
MSCs (referred to as fibroblastic colony-forming units), 
which are considered the functional cells establishing a 
progeny and responsible for bone tissue formation in vivo 
 [37] , are found at a very low frequency among bone mar-
row cells (1 in 10,000 nucleated cells)  [30] . Therefore, the 
reproducibility in the collection of sufficient numbers of 
MSC from various patients which are effective for direct 
grafting still requires confirmation.
 In contrast, the freshly isolated SVF of human adipose 
tissue might represent a better cell source for a one-step 
surgical procedure thanks to an up to 100-fold higher 
number of fibroblastic colony-forming units per volume 
of tissue sample compared to human bone marrow  [31, 
38] . Moreover, adipose tissue is available in large quanti-
ties and its harvest is associated with low morbidity  [39] . 
Two studies  [40, 41] tested the impact of SVF cells im-
planted intraoperatively in a goat spinal fusion model and 
demonstrated a superior bone healing with SVF cells 
than in cell-free scaffolds. Overall, healing was compa-
rable to that achieved with the gold standard of autolo-
gous bone grafting plus titanium cage. However, this or-
thotopic model could not investigate the direct osteogen-
ic contribution of the cells implanted. To achieve that, our 
group tested human SVF cells seeded onto porous hy-
droxyapatite scaffolds using fibrin gel in an ectopic nude 
mouse model. The study that freshly isolated SVF cells 
can ectopically generate osteoid structures but not frank 
bone tissue  [42] . More recent results indicate that low 
doses of BMP-2 are sufficient to instruct unmanipulated 
SVF to form bone tissue even at an ectopic site [unpubl. 
data], thus highlighting the importance of local growth 
factor concentrations at an orthotopic site.
 Interestingly, SVF cells not only include progenitors 
capable of osteogenesis, but also constitute a relevant res-
ervoir of vascular progenitors  [43] . We showed that nei-
ther mesenchymal CD34+CD31– nor endothelial CD34+ 
CD31+ cells from SVF were able to form vascular struc-
tures alone, but that their combination inside SVF result-
ed in a robust assembly of vascular structure in vitro  [32] . 
A study from our group confirmed that the vasculogenic 
potential of SVF cells does not require any in vitro pre-
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conditioning of SVF cells, but reproducibly and robustly 
takes place upon implantation of SVF cells in vivo  [42] .
 In conclusion, the intraoperative generation of osteo-
genic grafts with intrinsic vasculogenic properties using 
SVF cells has been proved to be feasible. A safe clinical 
translation of this paradigm now requires further valida-
tion in animal models (e.g. with orthotopic implantation 
and/or in immunocompetent animals) and the definition 
of quality control markers of the cells to predict their 
clinical performance prior to their implantation.
 Developmental Engineering
 A possible hint to identify an alternative improvement 
in current bone tissue engineering approaches has grown 
out of developmental biology studies. As a matter of fact, 
most tissue engineering strategies for bone regeneration 
resemble intramembranous ossification, i.e. the direct 
osteogenic differentiation of mesenchymal progenitors 
using a mineralized surface as ‘priming’ substrate  [25] , 
while most bones develop by endochondral ossification, 
which consists of remodeling a hypertrophic cartilagi-
nous template into bone. Indeed, upon in vivo implanta-
tion of in vitro generated hypertrophic cartilage tem-
plates, it is now possible to recapitulate and finalize the 
endochondral route  [44–46] . This very promising ap-
proach, initially demonstrated with embryonic stem cells 
 [45] , has recently been duplicated with the more clini-
cally compliant human MSC  [44] ( fig. 2 ). Most impor-
tantly, the underlying morphogenetic process was struc-
turally and molecularly similar to the temporal and spa-
tial progression of bone development in embryos. Overall, 
these studies paved the way for the design of clinically 
relevant strategies for bone regeneration and gave a proof 
of concept that it is possible to recapitulate embryonic 
processes with human MSC in order to engineer func-
tional tissue. However, besides being more ‘biomimetic’, 
the endochondral route presents several practical advan-
tages compared to the classic intramembranous ossifica-
tion-like approaches, such as (i) higher vasculogenic po-
tential thanks to the production of vascular endothelial 
growth factor by hypertrophic chondrocytes; (ii) osteoin-
ductivity thanks to the production of BMPs, and (iii) 
higher chances of survival in the hypoxic environment 
after implantation, because cartilage cells are equipped 
with poor environmental conditions for survival  [46] .
 The term ‘developmental engineering’ has recently 
been introduced into the scientific community by Lenas 
et al. [47, 48] for this innovative approach to tissue regen-
eration. The application of typical concepts of develop-
mental biology represents a paradigm change from the 
original, simplistic tissue engineering strategy of 3D cell 
growth on a scaffold  [47] . This new paradigm consists in 
engineering ‘processes’ recapitulating embryonic events 
rather than ‘tissues’. Recapitulating in vitro the complex-
ity of tissues and organ development may be a nearly im-
possible challenge. However, by activating the right de-
BM
a b
 Fig. 2.  a Masson’s trichrome staining of hyperthrophic cartilage tissue undergoing remodeling. BM = Bone 
marrow. Scale bar = 200   m.  b H&E staining of bone tissue obtained through endochondral ossification with 
a developmental engineering approach.  
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 Several issues remain to be addressed before a clinical 
exploitation of this approach can be planned. Especially 
the long in vitro culture makes a clinical translation dif-
ficult. However, this limitation can be overcome by the 
use of decellularized hypertrophic cartilage templates: 
these tissues may be engineered with an extracellular ma-
trix rich in growth factors, which may be sufficient to 
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and formation of bone over the remodeled template by 
host osteoprogenitors. Experimental studies are current-
ly exploring this strategy which can possibly lead to off-
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priming endochondral ossification.
 Conclusion
 In this review, we presented recent advances in bone 
tissue engineering focusing on three different mainstays 
of bone-regenerative strategies: (i) bioreactor-based tis-
sue manufacture; (ii) intraoperative strategies, and (iii) 
developmental engineering ( fig. 1 ). However, many other 
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tides; cytokines, or gradients) will be of paramount im-
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has to be applied in immunocompetent models which 
take inflammatory signals into account, which are now 
widely recognized to regulate and control bone regenera-
tion processes.
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